not vested
Nov 19, 2019
<Research Report>C Suisse Lifts BEIGENE (06160.HK) TP to $146.06; Rated Outperform
Credit Suisse commented in its report that BEIGENE (06160.HK) has received clearance for self-developed BRUKINSA from USFDA earlier than expected, which may accelerate relevant monetisation in the US.
The broker retained Outperform on BEIGENE at the target price $146.06, lifted from $122.65.
Source: AAStocks Financial News
|
|
Beigene 6160; BGNE
10 posts
• Page 1 of 1
Beigene 6160; BGNE
by winston » Tue Dec 17, 2019 2:11 pm
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160
by winston » Tue Dec 17, 2019 2:14 pm
not vested
Nov 15, 2019
<Research Report>BofAML Lifts BEIGENE (06160.HK) TP to $138.88, Rated Buy
Bank of America Merrill Lynch mentioned in its research report that BEIGENE (06160.HK)'s Brukinsa has recently received clearance from USFDA, which may start sales in the US in the coming two weeks.
The broker reiterated Buy on BEIGENE at the target price $138.88.
Source: AAStocks Financial News
Nov 15, 2019
<Research Report>BofAML Lifts BEIGENE (06160.HK) TP to $138.88, Rated Buy
Bank of America Merrill Lynch mentioned in its research report that BEIGENE (06160.HK)'s Brukinsa has recently received clearance from USFDA, which may start sales in the US in the coming two weeks.
The broker reiterated Buy on BEIGENE at the target price $138.88.
Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160
by winston » Tue Dec 17, 2019 2:16 pm
not vested
Nov 15, 2019
<Research Report>JPM Restates BEIGENE (06160.HK) at Overweight, TP $129
BEIGENE (06160.HK)'s self-discovered zanubrutinib (brand name: BRUKINSA) has received accelerated approval from the United States Food and Drug Administration as a treatment for mantle cell lymphoma in adult patients, who have received at least one prior therapy, mentioned JPMorgan in its report.
The broker regarded this as an important milestone for the firm, as zanubrutinib is the first BeiGene-discovered drug with approval.
BEIGENE was restated at Overweight, with a target of $129.
Source: AAStocks Financial News
Nov 15, 2019
<Research Report>JPM Restates BEIGENE (06160.HK) at Overweight, TP $129
BEIGENE (06160.HK)'s self-discovered zanubrutinib (brand name: BRUKINSA) has received accelerated approval from the United States Food and Drug Administration as a treatment for mantle cell lymphoma in adult patients, who have received at least one prior therapy, mentioned JPMorgan in its report.
The broker regarded this as an important milestone for the firm, as zanubrutinib is the first BeiGene-discovered drug with approval.
BEIGENE was restated at Overweight, with a target of $129.
Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160
by winston » Tue Dec 17, 2019 2:18 pm
not vested
Nov 13, 2019
BEIGENE (06160.HK) 1-3Q Loss Widens to US$307M
BEIGENE (06160.HK) announced that net loss for the first three quarters in 2019 amounted to US$307 million, widening from US$144 million a year ago.
LPS equaled US$0.39.
Source: AAStocks Financial News
Nov 13, 2019
BEIGENE (06160.HK) 1-3Q Loss Widens to US$307M
BEIGENE (06160.HK) announced that net loss for the first three quarters in 2019 amounted to US$307 million, widening from US$144 million a year ago.
LPS equaled US$0.39.
Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160
by winston » Tue Dec 17, 2019 2:24 pm
not vested
Nov 1, 2019
BEIGENE Rockets 38% to New High, 20.5% Stake Bought by Amgen
BEIGENE (06160.HK) skyrocketed 38% to $115.3, surpassing the peak at $108.2 since IPO, on volume of 1.08 million shares and turnover of $117 million.
BEIGENE announced that Amgen would acquire a 20.5% stake in the Company for US$2.7 billion (approximately HK$21.4 billion), with a subscription price of US$13.45 per share (equivalent to US$174.85 per ADS).
Source: AAStocks Financial News
Nov 1, 2019
BEIGENE Rockets 38% to New High, 20.5% Stake Bought by Amgen
BEIGENE (06160.HK) skyrocketed 38% to $115.3, surpassing the peak at $108.2 since IPO, on volume of 1.08 million shares and turnover of $117 million.
BEIGENE announced that Amgen would acquire a 20.5% stake in the Company for US$2.7 billion (approximately HK$21.4 billion), with a subscription price of US$13.45 per share (equivalent to US$174.85 per ADS).
Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160
by winston » Tue Dec 17, 2019 2:38 pm
not vested
BeiGene's zanubrutinib fails to beat Imbruvica in WM study; shares down 9% PM
Dec. 16, 2019
By Douglas W. House
BeiGene (NASDAQ:BGNE) is down 9% premarket on modest volume in reaction to results from a Phase 3 clinical trial, ASPEN, comparing BTK inhibitor Brukinsa (zanubrutinib) to AbbVie's (NYSE:ABBV) Imbruvica (ibrutinib) in patients with a type of lymphoma called Waldenström’s macroglobulinemia (WM).
The study failed to achieve the primary endpoint of demonstrating zanubrutinib's superiority to ibrutinib as measured by the proportion of patients experiencing either a complete response (CR) or very good partial response (VGPR) in up to three years.
In the overall patient population, the VGPR rate for zanubrutinib was 28.4% compared to 19.2% for ibrutinib.
In the relapsed/refractory population, the major response rate (partial response or better) was 78.3% for zanubrutinib and 80.2% for ibrutinib.
The safety profiles were generally similar.
Complete data will be submitted for presentation at a future medical conference.
ABBV is up a fraction premarket.
Source: Seeking Alpha
https://seekingalpha.com/news/3526409-b ... m=referral
BeiGene's zanubrutinib fails to beat Imbruvica in WM study; shares down 9% PM
Dec. 16, 2019
By Douglas W. House
BeiGene (NASDAQ:BGNE) is down 9% premarket on modest volume in reaction to results from a Phase 3 clinical trial, ASPEN, comparing BTK inhibitor Brukinsa (zanubrutinib) to AbbVie's (NYSE:ABBV) Imbruvica (ibrutinib) in patients with a type of lymphoma called Waldenström’s macroglobulinemia (WM).
The study failed to achieve the primary endpoint of demonstrating zanubrutinib's superiority to ibrutinib as measured by the proportion of patients experiencing either a complete response (CR) or very good partial response (VGPR) in up to three years.
In the overall patient population, the VGPR rate for zanubrutinib was 28.4% compared to 19.2% for ibrutinib.
In the relapsed/refractory population, the major response rate (partial response or better) was 78.3% for zanubrutinib and 80.2% for ibrutinib.
The safety profiles were generally similar.
Complete data will be submitted for presentation at a future medical conference.
ABBV is up a fraction premarket.
Source: Seeking Alpha
https://seekingalpha.com/news/3526409-b ... m=referral
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160; BGNE
by winston » Fri Mar 06, 2020 1:20 pm
not vested
What’s New
FY19 net loss widened by 41% to US$949m due to R&D and marketing expenses for new drugs,
below consensus estimates
Lower TP by 10% to HK$130 mainly to reflect slower-than-expected clinical development of a
product (Pamiparib)
Maintain BUY for seven catalysts in 12 months related to clinical development of two key
drugs and co-operation with Amgen
Source: DBS
https://researchwise.dbsvresearch.com/R ... cbackgaifc
What’s New
FY19 net loss widened by 41% to US$949m due to R&D and marketing expenses for new drugs,
below consensus estimates
Lower TP by 10% to HK$130 mainly to reflect slower-than-expected clinical development of a
product (Pamiparib)
Maintain BUY for seven catalysts in 12 months related to clinical development of two key
drugs and co-operation with Amgen
Source: DBS
https://researchwise.dbsvresearch.com/R ... cbackgaifc
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160; BGNE
by winston » Thu Jul 09, 2020 10:13 am
not vested
BEIGENE(6160)
Analysis：
BeiGene (6160) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
The Group announced that it had begun commercializing XGEVA® (denosumab) in China for the treatment of giant cell tumor of bone (GCTB).
This marks the first Amgen product that has been transitioned to BeiGene for commercialization in China since the commencement of the parties' global strategic oncology collaboration in January 2020.
The strategic collaboration also enables Amgen to deepen its commitment in China and build a more robust and complete portfolio in other chronic disease areas such as cardiovascular disease and fragility fracture to address the unmet needs of the aging population. (I do not hold the above stock).
Strategy：
Buy-in Price: $117.50, Target Price: $130.00, Cut Loss Price: $110.00
Source: Phillips
BEIGENE(6160)
Analysis：
BeiGene (6160) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
The Group announced that it had begun commercializing XGEVA® (denosumab) in China for the treatment of giant cell tumor of bone (GCTB).
This marks the first Amgen product that has been transitioned to BeiGene for commercialization in China since the commencement of the parties' global strategic oncology collaboration in January 2020.
The strategic collaboration also enables Amgen to deepen its commitment in China and build a more robust and complete portfolio in other chronic disease areas such as cardiovascular disease and fragility fracture to address the unmet needs of the aging population. (I do not hold the above stock).
Strategy：
Buy-in Price: $117.50, Target Price: $130.00, Cut Loss Price: $110.00
Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160; BGNE
by winston » Fri Dec 18, 2020 10:32 am
not vested
BEIGENE(6160)
Analysis：
BeiGene (6160) is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.
It currently markets two internally discovered oncology products: BTK inhibitor BRUKINSA (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.
It is committed to expediting the development of a diverse pipeline of novel therapeutics and is planning to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
(I do not hold the above stock)
Strategy：
Buy-in Price: $147, Target Price: $165, Cut Loss Price: $139
Source: Phillips
BEIGENE(6160)
Analysis：
BeiGene (6160) is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide.
It currently markets two internally discovered oncology products: BTK inhibitor BRUKINSA (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China.
It is committed to expediting the development of a diverse pipeline of novel therapeutics and is planning to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.
(I do not hold the above stock)
Strategy：
Buy-in Price: $147, Target Price: $165, Cut Loss Price: $139
Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
Re: Beigene 6160; BGNE
by winston » Tue Aug 16, 2022 4:14 pm
not vested
BeiGene (BGNE)
The first JPM pick is BeiGene, a clinical-stage biopharmaceutical company, with, in its words, ‘a broad and deep pipeline’ that takes a shotgun approach to the field of oncology.
The company is developing a tremendous number of drug candidates, more than 50, both in-house and as collaborative efforts, to address treatment needs in some 80% of cancer malignancies. A pipeline that size gives the company a competitive advantage when compared to peers.
BeiGene is a truly international biotech firm, operating in Asia, in Europe, and in the Americas, and boasting administrative offices in Beijing, China, Cambridge, Massachusetts, and Basel, Switzerland. From these offices, the company oversees its development activities, and the commercialization activities for its line of approved commercial-stage products.
The leading approved products are zanubrutinib, branded as Brukinsa, pamiparib, branded as Partruvix, and tislelizumab, branded under its own name. As a group, these drugs are approved in several international jurisdictions for the treatment of various hematological cancers and solid tumors.
BeiGene has been actively commercializing them for several years now, and in 2Q22 the company realized $304.5 million in total sales revenue. This number included $128.7 million from Brukinsa and $104.9 million in sales of tislelizumab in China.
The company’s total revenue, which includes collaboration fees, reached $341.6 million, compared to $150 million in the year-ago quarter.
Covering the stock for JPMorgan, analyst Xiling Chen believes BGNE presents a compelling risk reward. Kumar rates the stock an Overweight (i.e. Buy) along with a $296 price target that implies a 50% one-year upside.
Backing his bullish stance, Chen writes: "We see BeiGene shares as undervalued given quality of assets/growth and highlight the stock as one of our top picks in the sector...
BeiGene has grown into a fully integrated biopharma company with best-in-class clinical development capabilities, one of the largest and best oncology commercial platforms in China, and unmatched partnership skills with global biopharma companies.
We expect the company’s 16 commercial assets and broad pipeline to drive very attractive, diversified long-term growth. While we remain moderately below consensus on long-term sales, we see additional pipeline traction as upside to our estimates..."
Overall, 6 Wall Street analysts have chimed in on this biotech giant, and left 5 Buy recommendations against 1 Hold for a Strong Buy consensus rating. The shares are priced at $192.77 and their $253.76 average price target indicates an upside potential of ~29% in the coming months.
Source: TipRanks
BeiGene (BGNE)
The first JPM pick is BeiGene, a clinical-stage biopharmaceutical company, with, in its words, ‘a broad and deep pipeline’ that takes a shotgun approach to the field of oncology.
The company is developing a tremendous number of drug candidates, more than 50, both in-house and as collaborative efforts, to address treatment needs in some 80% of cancer malignancies. A pipeline that size gives the company a competitive advantage when compared to peers.
BeiGene is a truly international biotech firm, operating in Asia, in Europe, and in the Americas, and boasting administrative offices in Beijing, China, Cambridge, Massachusetts, and Basel, Switzerland. From these offices, the company oversees its development activities, and the commercialization activities for its line of approved commercial-stage products.
The leading approved products are zanubrutinib, branded as Brukinsa, pamiparib, branded as Partruvix, and tislelizumab, branded under its own name. As a group, these drugs are approved in several international jurisdictions for the treatment of various hematological cancers and solid tumors.
BeiGene has been actively commercializing them for several years now, and in 2Q22 the company realized $304.5 million in total sales revenue. This number included $128.7 million from Brukinsa and $104.9 million in sales of tislelizumab in China.
The company’s total revenue, which includes collaboration fees, reached $341.6 million, compared to $150 million in the year-ago quarter.
Covering the stock for JPMorgan, analyst Xiling Chen believes BGNE presents a compelling risk reward. Kumar rates the stock an Overweight (i.e. Buy) along with a $296 price target that implies a 50% one-year upside.
Backing his bullish stance, Chen writes: "We see BeiGene shares as undervalued given quality of assets/growth and highlight the stock as one of our top picks in the sector...
BeiGene has grown into a fully integrated biopharma company with best-in-class clinical development capabilities, one of the largest and best oncology commercial platforms in China, and unmatched partnership skills with global biopharma companies.
We expect the company’s 16 commercial assets and broad pipeline to drive very attractive, diversified long-term growth. While we remain moderately below consensus on long-term sales, we see additional pipeline traction as upside to our estimates..."
Overall, 6 Wall Street analysts have chimed in on this biotech giant, and left 5 Buy recommendations against 1 Hold for a Strong Buy consensus rating. The shares are priced at $192.77 and their $253.76 average price target indicates an upside potential of ~29% in the coming months.
Source: TipRanks
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
-
winston - Billionaire Boss
- Posts: 118900
- Joined: Wed May 07, 2008 9:28 am
10 posts
• Page 1 of 1
Who is online
Users browsing this forum: No registered users and 3 guests